Pharmaceuticals, Biotechnology and Life Sciences
DUBLIN–(BUSINESS WIRE)–The “Ibrance – Drug Insight, 2019” report has been added to ResearchAndMarkets.com’s offering. “Ibrance Drug Insight, 2019” highlights the…
DUBLIN–(BUSINESS WIRE)–The “Zeclar- Drug Insight, 2019” report has been added to ResearchAndMarkets.com’s offering. “Zeclar Drug Insight, 2019” highlights the drug…
Phase 1 clinical data show that subcutaneous administration of RUC-4 resulted in a potent, rapid, and sustained platelet inhibition effect;…
Mereo BioPharma Group’s Phase 2b dose-ranging “Asteroid” clinical study of setrusumab (BPS-804), an anti-sclerostin antibody, in adults with Type I,…
AstraZeneca and FibroGen’s pooled cardiovascular (CV) safety analyses showed that roxadustat, an oral first-in-class hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), did not increase the risk of MACE, MACE+ and all-cause mortality in non dialysis-dependent (NDD) patients compared to placebo and dialysis-dependent (DD) patients compared to epoetin alfa, a current medicine used to treat anaemia.
Vaccibody AS, a clinical-stage biopharmaceutical company focused on cancer vaccines, announced in a press release on November 5, 2019 the positive initial data from the ongoing VB N-01 (DIRECT-01) phase I/IIa clinical trial of the VB10.NEO neoantigen cancer vaccine.
3-Month Follow-up Data from the Fully Recruited Phase 2a Trial with a Total of 24 Patients Confirms Safety and Early…
– Study demonstrated statistically significant improvements in the overall study population with Type 2 or 3 SMA – – No…
—NOBILITY Phase II study showed 40% of patients treated with Gazyva plus standard of care achieved complete renal response at…
— Pooled Analysis from the FINCH RA Clinical Program with Investigational Filgotinib Reinforces Favorable Safety and Tolerability Profile Alone and…